Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6036MR)

This product GTTS-WQ6036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6036MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7246MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ7654MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ14995MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ3351MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ2367MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ14891MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ12000MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ7697MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW